South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook

African Journal of Laboratory Medicine

 
 
Field Value
 
Title South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook
 
Creator Hodkinson, Katherine E. Bouwer, Nikki Vaughan, Jenifer
 
Subject Medicine; Health Sciences; Haematology; Pathology chronic myeloid leukaemia; blast phase; major molecular route abnormalities; South Africa; p210 BCRABL1 fusion transcript; p190 BCRABL1 fusion transcript; responses by quantitative reverse transcriptase-polymerase chain reaction; karyotype
Description Background: Chronic myeloid leukaemia (CML) is a haematological malignancy characterised by the translocation t(9;22)(q34;q11.2), resulting in a constitutively active tyrosine kinase. Globally, overall survival of blast crisis phase (BC) CML is one year. Newer tyrosine kinase inhibitors and allogeneic stem cell transplantation offer remission; however, refractory and relapsed disease remain the biggest challenges.Objective: In South Africa, literature is lacking on BC-CML. This study aimed to determine the disease characteristics and overall survival in South Africa.Methods: This retrospective, laboratory-based study reviewed all new BC-CML diagnoses via flow cytometry at Charlotte Maxeke Johannesburg Academic Hospital in Johannesburg, South Africa, between April 2016 and October 2019. BC-CML was defined as the presence of 20% blasts with a CML history or the BCR-ABL1 fusion gene (p210/p190) in the appropriate clinical or pathological context. Survival outcomes were inferred from clinical and laboratory data.Results: Twenty-two new cases of BC-CML were diagnosed (median age: 34 years). There were 20 (91%) cases with the fusion transcripts p210 and two (9%) cases with p190 BCRABL1. For blast lineage, 14 cases were myeloid (63.6%), six were lymphoid (27.3%), and two were ambiguous (9.1%). There was a 72.7% mortality (16 cases); sepsis, refractory and relapsed disease were the major causes. Patients who achieved remission had lower blast percentages, simple karyotypes, and a trend towards higher white cell and platelet counts at presentation.Conclusion: Optimised management of early-stage CML, prevention and aggressive management of sepsis, with advocation for newer therapies are needed to improve the overall survival of BC-CML in South Africa. 
 
Publisher AOSIS
 
Contributor Nil
Date 2022-05-31
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Retrospective
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/ajlm.v11i1.1578
 
Source African Journal of Laboratory Medicine; Vol 11, No 1 (2022); 7 pages 2225-2010 2225-2002
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://ajlmonline.org/index.php/ajlm/article/view/1578/2234 https://ajlmonline.org/index.php/ajlm/article/view/1578/2235 https://ajlmonline.org/index.php/ajlm/article/view/1578/2236 https://ajlmonline.org/index.php/ajlm/article/view/1578/2237
 
Coverage — — Paediatrics; adults; male; female
Rights Copyright (c) 2022 Katherine E. Hodkinson, Nikki Bouwer, Jenifer Vaughan https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT